Critical Care & Emergencies (all articles) | Page 65 of 187 | Links Medicus Content Curation & Alerts in Medicine

J&J Covid-19 vaccination is associated with increased risk of cerebral venous sinus thrombosis.

2 Nov, 2021 | 03:02h | UTC

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination – JAMA

Commentary: Cerebral Venous Sinus Thrombosis Rate Up After Ad26.COV2.S Shot – HealthDay

Short Review: Ketamine for the treatment of acute pain.

2 Nov, 2021 | 02:43h | UTC

Ketamine for the treatment of acute pain – Canadian Medical Association Journal

Commentary on Twitter

If you manage pain in hospital, low-dose ketamine should be in your toolkit. And not just in the ED.

Quick overview with @WKSilverstein & @JonZipursky in @CMAJ: https://t.co/w5h3vIMiEK pic.twitter.com/gVO7W9dcYY

— David Juurlink (@DavidJuurlink) November 1, 2021

Cohort Study: Among patients with ST-segment elevation myocardial infarction, a concomitant Covid-19 diagnosis is associated with increased in-hospital mortality.

31 Oct, 2021 | 20:10h | UTC

Association Between COVID-19 Diagnosis and In-Hospital Mortality in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction – JAMA

Editorial: Myocardial Infarction During the COVID-19 Pandemic – JAMA

Commentary: STEMI and COVID-19 Often a Lethal Combo, Affirms Largest Study Yet – TCTMD

Commentary from the author on Twitter (thread – click for more)

1/8 It was not unexpected that pts w/ #STEMI would fare worse w/ than w/o #COVID19 https://t.co/B7oWnJunEa

— herbaronowMD (@herbaronowMD) October 29, 2021

Review: How I manage a patient with MRSA bacteremia.

31 Oct, 2021 | 19:54h | UTC

How I manage a patient with MRSA bacteraemia – Clinical Microbiology and Infection

Complications of critical COVID-19: Diagnostic and therapeutic considerations for the mechanically ventilated patient.

29 Oct, 2021 | 10:14h | UTC

Complications of critical COVID-19: Diagnostic and therapeutic considerations for the mechanically ventilated patient – Chest

2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain.

29 Oct, 2021 | 09:57h | UTC

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines – Journal of the American College of Cardiology

Executive Summary: 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain – Journal of the American College of Cardiology

News Release: First-Ever Guideline Focused Solely on Chest Pain Evaluation, Diagnosis Released

Guideline Hub: Guideline for the Evaluation and Diagnosis of Chest Pain

Key Points: 2021 AHA/ACC Chest Pain Guideline – American College of Cardiology

Commentary: New Chest Pain Guidelines Out at Last: Most Tests Have a Role – TCTMD

Commentary on Twitter (thread – click for more)

The Chest Pain Guidelines are now released!https://t.co/xQxCWzReEN
Top 10: CHEST PAINS
Thanks to the entire writing group and my co-cahirs: Deb Murkerjee & Phil Levy
💥First Chest Pain Guidelines @AHAScience @ACCinTouch pic.twitter.com/s17piamrKR

— Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 (@DrMarthaGulati) October 28, 2021

Brain injury after cardiac arrest: pathophysiology, treatment, and prognosis.

29 Oct, 2021 | 09:49h | UTC

Brain injury after cardiac arrest: pathophysiology, treatment, and prognosis – Intensive Care Medicine

Commentary on Twitter

Post-cardiac arrest brain injury, narrative review:
🧠pathophysiology: primary (ischemic) & secondary (reperfusion)
🧠treatment options
🧠outcomes
🧠neuroprognostication
🧠@ERC_resus @ESICM 2021 algorithm for prognostication
Open #FOAMcc #FOAMres @yourICM https://t.co/b8GRhE3MuF pic.twitter.com/q10DJVRJOp

— Intensive Care Medicine (@yourICM) October 27, 2021

RCT: Early treatment of Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab is associated with reduced risk of hospitalization.

28 Oct, 2021 | 10:20h | UTC

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab – New England Journal of Medicine

Commentary on Twitter

In this phase 3 trial, sotrovimab or placebo was administered to outpatients within 5 days after the onset of #COVID19 symptoms. Patients receiving sotrovimab had a lower incidence of hospitalization for any reason. #IDTwitter https://t.co/4VcgoK3xac pic.twitter.com/W82v3jNRmB

— NEJM (@NEJM) October 27, 2021

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

28 Oct, 2021 | 10:22h | UTC

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial – The Lancet Global Health

Commentaries:

Expert reaction to study looking at fluvoxamine as a COVID-19 treatment in high-risk outpatients with early-diagnosed COVID-19 – Science Media Centre

The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM

The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Commentary on Twitter

NEW in @LancetGH: Using SSRI #fluvoxamine to treat high-risk outpatients with early-diagnosed #COVID19 reduced the need for prolonged observation in an emergency setting or hospitalisation: largest trial to date. https://t.co/BVtMju74lp @TogetherTrial pic.twitter.com/F1FnZuyqdY

— The Lancet (@TheLancet) October 27, 2021

Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts.

28 Oct, 2021 | 10:11h | UTC

Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts – The Lancet Respiratory Medicine

Commentaries:

Respiratory Subphenotypes of COVID-19-Related ARDS – ICU Management & Practice

Commentary on Twitter

NEW—At baseline, #COVID19-related #ARDS has no consistent resp subphenotype. Pts diverged from fairly homogenous to a more heterogeneous popn, w/ trajectories of ventilatory ratio and mechanical power being the most discriminatory.

PRoVENT–COVID study: https://t.co/v8GTVcYLxq pic.twitter.com/Tv72jOzuAC

— The Lancet Respiratory Medicine (@LancetRespirMed) October 13, 2021

RCT: In critically ill patients, an individualized glucose control targeting an ICU patient’s pre-admission usual glycemia did not demonstrate a survival benefit compared to conventional glucose control (targeting glycemia below 180 mg/dL).

27 Oct, 2021 | 01:17h | UTC

Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study—a randomized clinical trial – Intensive Care Medicine

Editorial: The goal of personalized glucose control in the critically ill remains elusive – Intensive Care Medicine

Anticoagulants and diabetes agents are among the most frequent causes of emergency department visits attributed to medication harms.

27 Oct, 2021 | 01:15h | UTC

US Emergency Department Visits Attributed to Medication Harms, 2017-2019 – JAMA (link to abstract – $ for full-text)

Commentaries:

Number of emergency room visits for medication harms increases with age – MedicalResearch.com

Blood thinners, diabetes meds among top causes of drug-related ER visits – UPI

Systematic Review: Antibiotics for the treatment of COVID‐19 – “We are certain that risk of death in hospitalized COVID‐19 patients is not reduced by treatment with azithromycin after 28 days”.

26 Oct, 2021 | 02:07h | UTC

Antibiotics for the treatment of COVID‐19 – Cochrane Library

Commentary on Twitter

JUST PUBLISHED – Are #antibiotics an effective treatment for #COVID19 & do they cause unwanted effects? https://t.co/EVHduxmtdD New Cochrane Review looked at evidence from 11 studies: ❌ antibiotic azithromycin is not an effective treatment, 🤔not enough research on other types.

— The Cochrane Library (@CochraneLibrary) October 22, 2021

Cohort Study: Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia – “Bacterial superinfection within 48 hours of intubation was detected in 21 percent of patients”.

26 Oct, 2021 | 01:59h | UTC

Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia – American Journal of Respiratory and Critical Care Medicine

Commentary: Potential Overuse of Antibiotics Found in Patients with Severe COVID-19 Pneumonia – American Thoracic Society

Commentary on Twitter

Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia

🔓 Open Access
🔗 https://t.co/MaCZkKrQdQ pic.twitter.com/sscICvqYjS

— ATS Blue Journal (@ATSBlueEditor) October 19, 2021

Opinion | COVID STEROID-2: Double the steroid, double the fun? – “Dexamethasone 6 mg/day alone is likely suboptimal for most patients with severe COVID pneumonia. Dexamethasone 12 mg/day may provide a reasonable intensity of immunomodulation”.

25 Oct, 2021 | 00:01h | UTC

COVID STEROID-2: Double the steroid, double the fun? – PulmCrit

Original study: RCT: In adults with Covid-19 and severe hypoxemia, 12 mg vs. 6 mg of Dexamethasone did not result in a statistically significant difference in the number of days alive without life support.

Commentary on Twitter

COVID-STEROID 2
🥈5% lower mortality with 12 mg dexamethasone (vs 6 mg) – which is *huge* – but p=0.09 😩
🥈RCTs with toci/bari show that 6 mg dex alone is suboptimal.
🥈If using dex monotherapy, 12 mg is now a sensible dose for sicker pts.
Fresh blog: https://t.co/oPz7vAYHGN pic.twitter.com/diDqqUxSTC

— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) October 23, 2021

Review: Cardiac involvement in the long-term implications of COVID-19.

24 Oct, 2021 | 23:59h | UTC

Cardiac involvement in the long-term implications of COVID-19 – Nature Reviews Cardiology

2021 Interim Guidance to Health Care Providers for Basic and Advanced Cardiac Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19.

24 Oct, 2021 | 23:49h | UTC

2021 Interim Guidance to Health Care Providers for Basic and Advanced Cardiac Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19 – Circulation: Cardiovascular Quality and Outcomes

Commentary: CPR on a COVID Patient: Not a Moment to Waste Looking for PPE: Updated AHA guidance says resuscitation should not be delayed by mask availability – MedPage Today (free registration required)

Commentary on Twitter (thread – click for more)

(1/2) NEW! The AHA has published its 2021 interim CPR guidance for #HCPs who treat cardiac arrest patients with suspected or confirmed #COVID19. The paper in @CircOutcomes is an update to the 2020 Interim CPR Guidance: https://t.co/tuTwWkE0dL. pic.twitter.com/B1el7dCKJM

— AHA CPR & First Aid (@HeartCPR) October 13, 2021

RCT: In comatose survivors of out-of-hospital cardiac arrest, there was no difference in mortality and neurologic outcomes with mild (target temperature of 34 °C) vs. moderate therapeutic hypothermia (target temperature of 31 °C).

24 Oct, 2021 | 23:46h | UTC

Effect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The CAPITAL CHILL Randomized Clinical Trial – JAMA (free for a limited period)

Cooling After Cardiac Arrest – The Sclerosis of Therapeutic Fashion – “The story of how an ineffective therapy persisted for decades”

RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.

Study commentary: a history of hypothermia for cardiac arrest, 2002-2021 (RIP).

M-A: Targeted temperature management following out-of-hospital cardiac arrest – “Routine use of moderate or deep hypothermia in comatose survivors of OHCA may potentially be associated with more harm than benefit”.

Commentary on Twitter

therapeutic hypothermia after cardiac arrest is a nonbeneficial form of iatrogenesis that prolongs ICU length of stay (findings entirely consistent with TTM & TTM2). currently it should not be performed outside the context of an RCT. https://t.co/GZbpgHXWoD https://t.co/kRwRpLz6hV

— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) October 20, 2021

Guideline: Transfusion strategies in bleeding critically ill adults.

24 Oct, 2021 | 23:47h | UTC

Transfusion strategies in bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine – Intensive Care Medicine

Commentary on Twitter

Transfusion strategies in bleeding critically ill adults current evidence/research areas from @ESICM clinical practice guideline
🩸massive bleedings
🩸non‑massive bleedings
🩸tranexamic acid in traumatic/non‑traumatic hemorrhages
Open #FOAMcc on @yourICM
🖇️https://t.co/LtEzrLcaM5 pic.twitter.com/Po7eFYpdeW

— Intensive Care Medicine (@yourICM) October 22, 2021

The cost-effectiveness of cefazolin compared to anti-staphylococcal penicillins for the treatment of methicillin-sensitive Staphylococcus aureus bacteremia.

24 Oct, 2021 | 23:41h | UTC

The cost-effectiveness of cefazolin compared to anti-staphylococcal penicillins for the treatment of methicillin-sensitive Staphylococcus aureus bacteremia – Open Forum of Infectious Diseases

Meta-Analysis: Cefazolin vs. Anti-staphylococcal Penicillins for the Treatment of Staphylococcus aureus Bacteremia

Meta-Analysis: Cefazolin vs. Antistaphylococcal Penicillins for MSSA Bacteremia

Commentaries on Twitter

While Cefazolin and anti-staphylococcal penicillins (ASPs), such as nafcillin, are the preferred treatments for MSSA bacteremia it looks more and more like Cefazolin is really the preferred approach. https://t.co/6FVVEWMxBY

— Daniel Griffin MD PhD (@DanielGriffinMD) October 8, 2021

New in OFID: The use of cefazolin is a cost-effective strategy for the treatment of methicillin-sensitive S. aureus bacteremia and, when clinically appropriate, results in health care cost-savings.

📄: https://t.co/lRfsZdMjLJ #IDSAJournals @PaulSaxMD @DrJLi @ElMylonakis pic.twitter.com/hhzik4ppUW

— IDSA (@IDSAInfo) October 8, 2021

M-A: In patients with Staphylococcus aureus bacteremia, combination therapy does not reduce mortality and is associated with increased risks of adverse events.

24 Oct, 2021 | 23:42h | UTC

The Effect of Combination Therapy on Mortality and Adverse Events in Patients with Staphylococcus aureus Bacteraemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials – Infectious Diseases and Therapy

RCT: In adults with Covid-19 and severe hypoxemia, 12 mg vs. 6 mg of Dexamethasone did not result in a statistically significant difference in the number of days alive without life support.

22 Oct, 2021 | 10:32h | UTC

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial – JAMA

Editorial: Glucocorticoid Dose in COVID-19: Lessons for Clinical Trials During a Pandemic – JAMA

Commentary on Twitter

In a randomized trial of patients with #COVID19 and severe hypoxemia, compared with 6 mg of dexamethasone, 12 mg of dexamethasone did not statistically significantly reduce the number of days alive without life support at 28 days https://t.co/BMgLTel4aU pic.twitter.com/WKwI8xCUYO

— JAMA (@JAMA_current) October 21, 2021